Pfizer stock: Still priced like it's dead money

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
StockStory.org on MSN

Pfizer (NYSE:PFE) posts better-than-expected sales in Q1 CY2026

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On ...

Jim Cramer on Pfizer: “If I Want Good Yield, I’ll Buy a Bond”

Pfizer Inc. (NYSE:PFE) was among the stocks on Jim Cramer’s radar on Mad Money as he discussed the upcoming earnings. Cramer ...
24/7 Wall St.

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...
BioSpace

Pfizer is a 2029 story but Q126 lays foundation for growth

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
Seeking Alpha

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

If I am a Pfizer Inc. (PFE) investor (I used to be, nonetheless), I should have been "elated" at PFE's recent performance against the market, while still getting rewarded with a forward yield that ...